Retatrutide

For Laboratory Research Use Only — Not for Human or Veterinary Use.

Standard (< 1,000 vials)$230/kit

Volume (1,000+ vials)$150/kit

Quantity (kits)

= 10 vials

Minimum order: 100 vials total. Mix and match across all products.

I confirm this order is for laboratory research use only.For Laboratory Research Use Only — Not for Human or Veterinary Use. By checking this box you affirm this product will not be used for human or animal administration.

Specifications

CAS Number	2381089-83-2
Molecular Formula	C221H342N46O68
Molecular Weight	4731.27 g/mol
Purity	≥98% (HPLC)
Form	Lyophilized Powder
Storage	-20°C, desiccated, protected from light
Reconstitution	Bacteriostatic water

Certificate of Analysis

Lot documentation

Every production lot is independently third-party tested. A batch-specific Certificate of Analysis — documenting HPLC purity, mass spectrometry identity confirmation, and net peptide content — is issued with every shipment. View a sample COA to see the format.

View Sample COA About our testing →

Research context

Retatrutide is a synthetic peptide investigated as a triple agonist of the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCGR) receptors — three class B G-protein-coupled receptors involved in metabolic signaling. Like other long-acting incretin analogs, it incorporates a fatty-acid modification intended to prolong its half-life. It has been studied in vitro and in animal models as an agonist engaging all three receptor pathways.

Research into Retatrutide has focused on its simultaneous engagement of the GLP-1, GIP, and glucagon receptors, the balance of downstream signaling across these targets, and metabolic endpoints in isolated cell and rodent models. Analytical characterization has centered on HPLC purity assessment and mass-spectrometry identity confirmation.

This compound is supplied strictly for in-vitro laboratory research and analytical use. It is not intended for human or veterinary administration, and no statements herein constitute a therapeutic claim or dosing recommendation.